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https://doi.org/10.1016/j.ccell.2019.04.003SUMMARYAlthough immune checkpoint blockers have yielded significant clinical benefits in patients with different ma-
lignancies, the efficacy of these therapies is still limited. Here, we show that disruption of transmembrane
protein 176B (TMEM176B) contributes to CD8+ T cell-mediated tumor growth inhibition by unleashing
inflammasome activation. Lack of Tmem176b enhances the antitumor activity of anti-CTLA-4 antibodies
through mechanisms involving caspase-1/IL-1b activation. Accordingly, patients responding to checkpoint
blockade therapies display an activated inflammasome signature. Finally, we identify BayK8644 as a potent
TMEM176B inhibitor that promotes CD8+ T cell-mediated tumor control and reinforces the antitumor activity
of both anti-CTLA-4 and anti-PD-1 antibodies. Thus, pharmacologic de-repression of the inflammasome by
targeting TMEM176B may enhance the therapeutic efficacy of immune checkpoint blockers.INTRODUCTION
Blockade of immune checkpoints, including the cytotoxic T
lymphocyte-associated protein (CTLA)-4 and the programmed
cell death-1 (PD-1)/PD ligand-1 (PD-L1) pathway, have increased
overall survival and progression-free survival of cancer patients.Significance
Therapies targeting immune checkpoint pathways have revolu
adaptive mechanisms may limit the clinical efficacy of this t
protein 176B (TMEM176B) as an innate immune checkpoint th
flammasome activation. Genetic disruption or pharmacologic
enhances the efficacy of anti-CTLA-4 and anti-PD-1 antibodie
ingly, an activated inflammasome signature delineates favorabl
blockers. Thus, targeting TMEM176B may influence antitum
activation.
Cancer Cell 35, 767–781
This is an open access article undHowever, only a restricted number of patients show clinical ben-
efits (Syn et al., 2017; Binnewies et al., 2018), suggesting that
other immune inhibitory mechanisms may limit the efficacy of
these treatments. In this regard, high intratumoral K+ leads to
T cell dysfunction by inhibiting voltage and Ca2+-dependent K+
channels expressed in antitumoral T lymphocytes (Eil et al.,tionized treatment of several cancers. However, innate and
herapeutic modality. Here, we identify the transmembrane
at curtails CD8+ T cell-mediated immunity by repressing in-
inhibition of TMEM176B potentiates antitumor immunity and
s in mice by unleashing inflammasome activation. Accord-
e clinical responses in patients receiving immune checkpoint
or effector mechanisms by de-repressing inflammasome
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2016), suggesting a role for ionic channels as regulatory check-
points and therapeutic targets to reinforce antitumor immunity.
Recognition of immunogenic tumors by innate immune sen-
sors including the TMEM173 (STING) type I interferon pathway
leads to stimulation of CD8+ T cell-mediated immunity and
potentiation of CTLA-4- and PD-1-targeted therapies (Woo
et al., 2014). Within the human myeloid compartment, STING
controls the NLRP3 inflammasome (Gaidt et al., 2017), a cyto-
solic multiprotein complex that, once activated, cleaves cas-
pase-1, which then processes pro-interleukin-1b (IL-1b) and
pro-IL-18 to give the active and secreted forms of these
pro-inflammatory cytokines (Rathinam and Fitzgerald, 2016).
Altered levels of cytosolic cations have been shown to control
secretion of active IL-1b through modulation of inflammasome
activation (Gong et al., 2018). Interestingly, activation of the
NLRP3 inflammasome following immunogenic chemotherapy
sensitizes tumors to immune checkpoint blockers (Pfirschke
et al., 2016). However, the role of the NLRP3 inflammasome
in modulating checkpoint blockade therapies has not yet
been explored.
Transmembrane protein 176B (TMEM176B), also known as
tolerance-related and induced (TORID), has been identified as
an immunoregulatory cation channel (Louvet et al., 2005; Segovia
et al., 2014). This ubiquitously expressed protein contains four
transmembrane domains and an ITIM motif in its C terminus
(Eon Kuek et al., 2016). TMEM176B and its homologous
TMEM176A are members of the CD20-like MS4A family of pro-
teins (Eon Kuek et al., 2016; Louvet et al., 2005) and are highly ex-
pressed inmonocytes,macrophages, andCD11b+ dendritic cells
(DCs) (Condamine et al., 2010). Here we explored the role of
TMEM176B in inflammasome regulation, T cell-dependent anti-
tumor immunity and response to immune checkpoint blockade
therapies.Figure 1. The Ionic Channel TMEM176B Inhibits the NLRP3 Inflammas
(A) Representative dot plots and absolute number of neutrophils (CD11b+ Ly6Cin
control (PBS) or 20 mg/kg ATP. In the plots, CD11b+ cells were analyzed for Ly6C
independent experiments. ns, not significant; *p < 0.05; one-way ANOVA test.
(B and C) Dose-response (B) and time-response (C) analysis of WT and Tmem176
washed and treated with ATP (left) or nigericine (Nig) (right). IL-1b in culture sup
shown. *p < 0.05, **p < 0.01; two-way ANOVA test.
(D) Western blot analysis of pro-IL-1b and pro-caspase-1 (lysates) or IL-1b and ca
as in (B and C) and then treated for 90 min with 2.5 mM Nig or 0.5 mM ATP. One
(E) Caspase-1 activation inWT and Tmem176b/BMDCs treated with LPS and t
stained with FLICA1 reagent. One experiment representative of three is shown. *
(F) IL-1b secretion byWT and Tmem176b/BMDCs treated as in (E) compared w
representative of three is shown. **p < 0.01, ****p < 0.0001; two-way ANOVA tes
(G and H) Determination of IL-1b (G) and IL-18 (H) by ELISA in culture supernatan
(E). One experiment representative of two is shown. *p < 0.05, **p < 0.01, ****p <
(I) Determination of IL-1b in culture supernatants of THP-1-differentiated macro
0.25 mg/mL LPS and then for 2 h with 2.5 mM Nig. One experiment representativ
(J) Calcium determination in WT and Tmem176b/ BMDCs treated for 3 h with 0
Fura-2. Emission at 340/380 nm was recorded in time-lapse experiments; 0.5 m
(K) Determination of IL-1b in BMDCs exposed to the NLRP3 inflammasome activa
chelator BAPTA (100 mM) or DMSO vehicle control. One experiment representat
(L) Determination of IL-1b in BMDCs following inflammasome activation in the p
representative of three is shown. *p < 0.05; two-way ANOVA test.
(M and N) Determination of IL-1b in BMDCs following inflammasome activation in t
(IbTx) in (M) or hydroxychloroquine (HCQ) in (N). One experiment representative
In ELISA experiments, ND stands for not detected.
Mean ± SD are shown.
See also Figure S1.RESULTS
TMEM176B Inhibits Activation of the NLRP3
Inflammasome
To investigate whether TMEM176B regulates inflammasome
activation, we injected ATP in wild-type (WT) or Tmem176b/
mice (Figure 1A). In this model, neutrophil recruitment to the
peritoneal cavity relies on caspase-1/11 activation (Schroeder
et al., 2017). We observed that Tmem176b/ mice recruited
significantly more neutrophils than WT animals. To determine
whether increased neutrophil recruitment upon ATP injection
was dependent on inflammasome activation, we generated
Tmem176b/Casp1/ double knockout (DKO) mice (Fig-
ure S1A). Peritoneal neutrophil recruitment was almost
completely inhibited in Tmem176b/Casp1/ compared with
Tmem176b/ animals (Figure 1A). ATP-induced neutrophil
recruitment in Tmem176b/mice was also interrupted by injec-
tion of a caspase-1 inhibitor (Figure S1B). We then stimulated
WT and Tmem176b/ bone marrow-derived DCs (BMDCs)
with the well-established NLRP3 activators ATP and nigericin
and determined IL-1b in culture supernatants as a readout of
inflammasome activation. We observed that, for both stimuli,
Tmem176b/ BMDCs secreted significantly higher levels of
IL-1b than WT DCs in a dose- and time-dependent manner
(Figures 1B and 1C). Similar findings were observed when
we stimulated BMDCs with aluminum particles (Figure S1C).
Western blot studies confirmed that the mature (cleaved)
form of IL-1b was more abundant in culture supernatants from
Tmem176b/ BMDCs compared with those obtained from
WT cells (Figure 1D). Moreover, we observed increased
mature caspase-1 in supernatants from Tmem176b/ BMDCs
compared with WT cells when stimulated with ATP (Figure 1D).
Although lower doses (2.5 mM) of nigericin induced expression ofome
t Ly6G+) in peritoneal lavage 4 h after intraperitoneal (i.p.) injection with vehicle
and Ly6G expression. At least six animals were studied in each group in two
b/ bone marrow-derived DCs (BMDCs) treated with LPS (0.25 mg/mL) for 4 h,
ernatants was determined by ELISA. One experiment representative of five is
spase-1 (supernatants) in WT and Tmem176b/ BMDCs stimulated with LPS
experiment representative of three is shown.
hen exposed to 0.5 mM ATP or 2.5 mMNig for 45min. Cells were harvested and
p < 0.05; two-way ANOVA test.
ith those treated with 10 mMZ-WEHD-FMK 15min before ATP. One experiment
t.
ts from WT, Tmem176b/, and Tmem176b/Casp1/ BMDCs treated as in
0.0001; two-way ANOVA test.
phages expressing GFP or GFP-TMEM176B untreated or treated for 3 h with
e of four is shown. **p < 0.01, ***p < 0.001; two-way ANOVA test.
.25 mg/mL LPS and 0.5 mM ATP. Cells were loaded with Ca2+-sensitive probe
M ATP was added when indicated by the arrow. Scale bars, 10 mm.
tor ATP as described in (E) in the presence or absence of the intracellular Ca2+
ive of three is shown. *p < 0.05; two-way ANOVA test.
resence of control buffer (5 mM) or high K+ buffer (120 mM). One experiment
he presence or absence of the Ca2+-activated K+ channels blockers iberiotoxin
of three is shown in each case. *p < 0.05, **p < 0.01; two-way ANOVA test.
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mature caspase-1 in culture supernatants from Tmem176b/
but not WT BMDCs (Figure 1D), higher doses (5 mM) of this
NLRP3 activator induced cleavage of caspase-1 in WT DCs,
whereas lipopolysaccharides (LPS) alone did not (Figure S1D).
In agreement with this observation, flow cytometry studies using
the FLICA1 reagent revealed higher caspase-1 activation in
Tmem176b/ BMDCs (Figure 1E), suggesting that caspase-1
may contribute to mature IL-1b secretion by Tmem176b/
BMDCs. To confirm these findings, we induced inflammasome
activation in WT and Tmem176b/ BMDCs in the presence or
absence of a caspase-1 inhibitor and found that IL-1b secretion
was completely inhibited when caspase-1 activation was inter-
rupted (Figure 1F). Moreover, IL-1b secretion was completely
abrogated in Tmem176b/Casp1/ BMDCs (Figure 1G).
Thus, increased IL-1b secretion observed as a result of
Tmem176b deficiency requires intact caspase-1 activity. More-
over, Tmem176b/ BMDCs also secreted higher amounts of
IL-18 compared with WT cells in a caspase-1-dependent
manner (Figure 1H).
We then speculated that TMEM176B overexpression may
impair IL-1b secretion in cells in which the inflammasome was
activated. To address this issue, THP-1-differentiated macro-
phages were transfected with TMEM176B/GFP or GFP alone
(Figure S1E) and then treated with LPS and nigericin. TMEM176B
overexpression impaired IL-1b secretion compared with GFP-
expressing cells (Figure 1I); this effect was not associated with
increased cell death (Figure S1F). Thus, cation channel
TMEM176B inhibits activation of the NLRP3 inflammasome. On
the other hand, TMEM176B expression in BMDCs appears to
be modulated, at least in part, by inflammasome activation (Fig-
ure S1G), suggesting bidirectional regulation of these pathways.
Of note, lower TMEM176B expression was not associated with
widespread inhibition of inflammatory mediators (Figure S1G) or
with increased cell death (Figure S1H) in inflammasome-stimu-
lated BMDCs.
TMEM176B Inhibits the Inflammasome through the
Control of Cytosolic Ca2+
TMEM176B is an endophagosomal non-selective monovalent
cation channel (Segovia et al., 2014). Because the NLRP3 inflam-
masome is tightly regulated by cytosolic K+ (Muñoz-Planillo
et al., 2013) and Ca2+ (Murakami et al., 2012) levels, we specu-
lated that TMEM176B may inhibit inflammasome activation
through the regulation of ion homeostasis. To address this ques-
tion, we first determined cytosolic Ca2+ levels in WT and
Tmem176b/ BMDCs stimulated with ATP. BMDCs lacking
Tmem176b showed greater cytosolic Ca2+ as compared with
WT BMDCs (Figure 1J). Interestingly, intracellular Ca2+ chelation
completely blocked IL-1b secretion in WT and Tmem176b/
BMDCs (Figure 1K). This effect was also dependent on K+ efflux
in WT and Tmem176b/ BMDCs (Figure 1L).
We recently showed that Ca2+-activated K+ channels are
involved in ATP-triggered inflammasome activation (Schroeder
et al., 2017). We therefore inhibited Ca2+-activated K+ channels
in ATP-treated WT and Tmem176b/ BMDCs and determined
the amounts of IL-1b in culture supernatants. Inhibition of
channel function using iberiotoxin or hydroxychloroquine
(Schroeder et al., 2017) led to dose-dependent reduction in
IL-1b secretion by WT BMDCs. Interestingly, IL-1b secretion770 Cancer Cell 35, 767–781, May 13, 2019by Tmem176b/ BMDCs was completely abrogated by both
inhibitors at doses that partially inhibited IL-1b secretion in
WT BMDCs (Figures 1M and 1N). Thus, heightened inflamma-
some activation in Tmem176b/ BMDCs is highly dependent
on Ca2+-activated K+ channels. These results suggest that
TMEM176B impairs ATP-induced cytosolic Ca2+ accumulation,
preventing Ca2+-dependent K+ channel-driven inflammasome
activation.
Lack of Tmem176bRestrains Tumor Growth in an IL-1b-
and Caspase-1-Dependent Manner
To investigate whether TMEM176B-mediated regulation of in-
flammasome activation may influence antitumor immunity, we
first examined the relevance of TMEM176B expression in
humancancer.HighstromalTMEM176Bexpression incoloncan-
cerwas associatedwith significantly lower overall patient survival
(FiguresS2A andS2B).Moreover,wedetected a strikingnegative
correlation between TMEM176B and NLRP3/IL1B expression
from single-cell RNA sequencing analysis in macrophages infil-
trating human melanoma (data analyzed from Jerby-Arnon
et al., 2018), suggesting a role for this axis in the tumor micro-
environment (Figure S2C). Accordingly, Tmem176b/ mice
inoculated with MC38 (colon), LL/2 (LLC1; lung), or EG7 (thymic
lymphoma) cell lines showed higher survival (Figure 2A) and
reduced tumor growth (Figure S2D) compared with WT mice.
Although TMEM176B is expressed by the three tumor cell
lines studied (Figure S2E), immune cells from tumor-bearing
Tmem176b/animalsdidnot showenhanced in vivocytotoxicity
against WT cells compared with tumor-bearing Tmem176b+/+
mice (Figure S2F), suggesting that tumor-associated TMEM176B
is not immunogenic in Tmem176b/ hosts.
To investigate the mechanisms underlying TMEM176B contri-
bution to tumor growth, we studied inflammasome activation
and found no differences in caspase-1 activation in tumors devel-
oped in WT and Tmem176b/ mice (Figure S2G). However, we
found increased caspase-1 activation in tumor-draining lymph
nodes (TDLN) from Tmem176b/ mice compared with WT ani-
mals (Figures2B–2E).Moreover, flowcytometryanalysis revealed
augmented caspase-1 activation in resident CD11chi MHC II+
CD11b+classicalDCs (cDCs) in TDLN fromTmem176b/ versus
WT tumor-bearingmice (Figures 2F, 2G, and S2H).Migratory and
resident cDCs were discriminated based on CD11c and MHC II
expression (FigureS2H) asdescribed (Laoui et al., 2016). Interest-
ingly, CD11chi MHC II+ CD11b+ cDCs expressed considerable
amounts of TMEM176B (Crozat et al., 2011) and TDLN contained
higher frequency of CD11b+ TMEM176B+ cells compared with
lymph nodes from naive animals (Figure S2I).
Since CD11b+ cDCs induce differentiation of Th17 cells (Durai
and Murphy, 2016), we speculated that this CD4+ T cell subset
may augment in TDLN from Tmem176b/ mice. We observed
increased frequency of TCRb+ CD4+ RORgt+ cells in TDLN
from Tmem176b/ animals compared with WT and anti-IL-
1b-treated Tmem176b/ mice (Figure S2J). Moreover, in vitro
re-stimulation of TDLN cells with ovalbumin (OVA) showed
increased proportion of IL-17+ CD4+ T cells in Tmem176b/
compared with WT mice (Figure S2K), and in vivo IL-17A
blockade showed a clear trend toward suppression of the anti-
tumor effect in tumor-bearing Tmem176b/ mice (Figure S2L).
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frequency of functional TCRb+ CD4+ RORgt+ IL-17+ T cells in an
inflammasome-dependent manner.
To study whether increased inflammasome activation could be
responsible for tumor control in mice lacking Tmem176b, we
blocked IL-1b and studied EG7 tumor development. Treatment
with anti-IL-1b-neutralizing antibodies, but notwith control immu-
noglobulin G, eliminated the antitumor activity displayed by
Tmem176b/ mice (Figure 2H). This effect was also verified in
Tmem176b/Casp1/DKOmice (Figure 2I). These results sug-
gest that diminished tumor growth observed in Tmem176b/
mice depends on inflammasome activation.
To further examine the cellular effectors involved in tumor
growth inhibition in Tmem176b/ mice, we analyzed a panel of
immunological mediators by qRT-PCR and found no differences
between tumorsgrown inWTorTmem176b/mice (FigureS3A).
Moreover,wedid not find significant changes in thepercentageor
absolute number of infiltrating myeloid, B, NK, NKT, or CD4+
TcellsbetweenWTandTmem176b/ tumors (FigureS3B).How-
ever, the percentage of total CD8+ T cells within tumor infiltrates,
as well as the absolute number of total and tumor-specific CD8+
T cells, was considerably increased in tumors grown in
Tmem176b/ mice compared with those developed in WT
mice (Figures S4A and S4B). Although the absolute number of
CD4+ CD25+ Foxp3+ regulatory T (Treg) cells was higher in
tumors developed in Tmem176b/ versus WT animals, an
increased effector T cell (CD8)/Treg (Foxp3) ratio was apparent
(Figure S4C). Moreover, tumor-infiltrating CD8+ T cells from
Tmem176b/ mice showed greater proliferation compared
with those obtained from WT animals when re-stimulated in vitro
with OVA MHC I peptide (Figure S4D). Interestingly, we found
downregulation of the Treg-related molecules Foxp3, CTLA-4,
CCL5, CCL19, and CCL22 in TDLN from Tmem176b/ versus
WT mice (Figure S3A). Moreover, decreased percentages but
not absolute numbers of TCRb+ CD4+ Foxp3+ Treg cells were
observed in TDLN from Tmem176b/ versus WT mice, andFigure 2. Mice Lacking Tmem176b Control Tumor Growth through an
(A) Survival of WT and Tmem176b/ mice injected subcutaneously with MC38 c
graph), or EG7 thymic lymphoma cells (1 3 106; right graph). Mice survival was m
injected mice from three experiments. *p < 0.05, **p < 0.01; log rank (Mantel-Co
(B and C) Western blot analysis (B) and semiquantification (C) of pro-caspase-1 a
Tmem176b/ mice. At least four animals/group are shown. *p < 0.05; Student’s
(D and E) Confocal microscopy (D) and semiquantification (E) of activated caspase
n = 3 each group. *p < 0.05, ***p < 0.001; one-way ANOVA test.
(F) Flow cytometry analysis of FLICA1+ cells within TDLN. SSC, Side scatter. On
(G) Evaluation of FLICA1+ CD11b+ and CD11b classical DCs (cDCs) in TDLN is
(H) Survival of Tmem176b/ EG7 tumor-bearing mice treated with anti-IL-1b o
surviving animals/total injected mice from one experiment. *p < 0.05; log rank (M
(I) Survival of untreated Tmem176b/ and Tmem176b/Casp1/ EG7 tumor-be
pooled from three independent experiments. *p < 0.05; log rank (Mantel-Cox) te
(J) In vivo cytotoxicity against OVA-expressing cells in WT and Tmem176b/ EG
each group are shown. **p < 0.01; Student’s t test.
(K) In vivo cytotoxicity against OVA-expressing cells in EG7 tumor-bearing Tme
*p < 0.05; Student’s t test.
(L) In vivo cytotoxicity against OVA-expressing cells in tumor-bearing Tmem17
shown. *p < 0.05; Student’s t test.
(M) Survival of tumor-bearing WT and Tmem176b/ mice left untreated or treate
animals/total injected mice. Data from one experiment are shown. *p < 0.05; log
The genetic background of the animals used was C57BL/6.
Mean ± SD are shown.
See also Figures S2–S5.
772 Cancer Cell 35, 767–781, May 13, 2019the CD8/Treg ratio in TDLN was significantly increased in
Tmem176b/ mice (Figures S5A and B). In vivo, MHC I-depen-
dent CD8+ T cell-mediated cytotoxicity against OVA-expressing
cells was increased in tumor-bearing Tmem176b/ compared
with WT mice (Figures 2J and S5C). This effect was prevented in
Tmem176b/ animals treated with anti-IL-1b antibodies (Fig-
ure 2K) as well as in Tmem176b/Casp1/ animals (Figure 2L).
Within the tumor microenvironment, CTLs from Tmem176b/
Casp1/ animals expressed lower levels of the degranulation
markerCD107a than those fromTmem176b/mice (FigureS5D).
Interestingly, depletion of CTLs in Tmem176b/ mice using an
anti-CD8 antibody increased tumor growth to similar levels as
thoseobserved inWTmice (Figure2M).Thus,Tmem176bdeletion
enhances CTL-mediated tumor control through mechanisms
involving the caspase-1/IL-1b pathway. This mechanism is
associated with inflammasome-dependent induction of TCRb+
CD4+ RORgt+ cells. Altogether, these results support a role for
TMEM176Basanemerging immunecheckpoint that interrupts in-
flammasome activation and links innate and adaptive antitumor
responses.
Inflammasome Activation Reinforces Immune
Checkpoint Blockade Therapies
Given the influence of Tmem176b deletion in antitumor immu-
nity, we investigated whether targeting this ion channel might
control the efficacy of immune checkpoint blockade. We found
increased survival of Tmem176b/ compared with WT tumor-
bearing mice following treatment with anti-CTLA-4 monoclonal
antibody (mAb) (Figure 3A). This effect was dependent on inflam-
masome activation, as it was abrogated in Tmem176b/
Casp1/ animals (Figure 3A). To investigate this further, we in-
jected anti-CTLA-4 or anti-PD-1 mAb in EG7 tumor-bearing
Casp1/11/ or Nlrp3/ mice. Lack of Casp1/11 eliminated
the antitumor effects triggered by CTLA-4 or PD-1 blockade (Fig-
ure 3B). Although the experiments performed in Nlrp3/ miceIL-1b- and caspase-1-Dependent Manner
olon cancer cells (1 3 106; left graph), LL2 lung cancer cells (1 3 105; central
onitored every 3 days. The ratio shows the number of surviving animals/total
x) test.
nd caspase-1 expression in tumor-draining lymph nodes (TDLN) from WT and
t test.
-1 expression using the FLICA1 fluorescent probe in TDLN. Scale bars, 10 mm.
e experiment representative of two is shown.
shown. ns, not significant; ***p < 0.001; Student’s t test.
r control immunoglobulin G (IgG) antibodies. The ratio shows the number of
antel-Cox) test.
aringmice. The ratio shows the number of surviving animals/total injectedmice
st.
7 tumor-bearing mice. Data from four different animals and one experiment in
m176b/ mice treated with anti-IL-1b neutralizing or control IgG antibodies.
6b/ versus Tmem176b/Casp1/ mice. Data from two experiments are
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Figure 3. Inflammasome Activation Reinforces Immune Checkpoint Blockade
(A) Survival of WT, Tmem176b/, and Tmem176b/Casp1/ mice inoculated with EG7 tumor cells and receiving anti-CTLA-4 or control IgG antibodies.
*p < 0.05; log rank (Mantel-Cox) test.
(B and C) Survival of WT and Casp1/11/ (B) or Nlrp3/ (C) mice inoculated with EG7 tumor cells and injected with control IgG, anti-CTLA-4, or anti-PD-1
antibodies. ns, not significant; *p < 0.05; log rank (Mantel-Cox) test.
Data from three (A and B) or two (C) experiments are shown. The ratio depicts the number of surviving animals/total injected mice.did not reach statistical significance, there was a trend toward
lower survival in those mice when treated with anti-CTLA-4 or
anti-PD-1 mAb (Figure 3C). Moreover, we found no differences
in tumor growth in mice lacking inflammasome components un-
der control conditions (Figures 3B and 3C), in agreement with
previous reports (Ghiringhelli et al., 2009). These results highlight
the importance of triggering inflammasome activation to improve
the efficacy of checkpoint blockade therapies.
Sensitivity to Immune Checkpoint Blockers Is
Associated with an ‘‘Inflammasome-Activated’’
Signature in Cancer Patients
We then investigated whether inflammasome-related genes
might be associated with clinical responses in patients treated
with immune checkpoint blockers. First, we analyzed whole-
exome sequencing and transcriptomics data from a cohort of
melanoma patients treated with immune checkpoint inhibitors
(Riaz et al., 2017). These studies focused on pre-treatment andon-treatment tumor biopsies from patients receiving anti-PD-1
mAb after progression from anti-CTLA-4 therapy (IPI-progress-
ing) and patients treated with anti-PD-1 without previous anti-
CTLA-4 treatment (IPI-naive). In non-responding patients of the
IPI-naive population, only two inflammasome-related genes—
TMEM176A and TMEM176B—were significantly upregulated
during treatment compared with pre-treatment (Figure 4A; Table
S1). These observations emphasize the role of TMEM176 ionic
channels as potential mediators of resistance to checkpoint
blockade therapies.
Interestingly, when comparing patients responding or not to
anti-PD-1 at the pre-treatment stage, we found no significant
differences in inflammasome-related genes in the entire popu-
lation (Table S2), or in the IPI-naive (Table S3) or IPI-progressed
(Table S4) groups. However, eight inflammasome-related
genes were significantly upregulated in responders versus
non-responders in the entire population during anti-PD-1 treat-
















































































































































































































































Figure 4. Analysis of the Inflammasome Signature in Tumor Biopsies from Melanoma Patients Treated with Immune Checkpoint Blockers
(A) Paired analysis comparing pre-treatment versus on-treatment melanoma biopsies of patients who did not respond to anti-PD-1 therapy and were not treated
previously with anti-CTLA-4 antibody (IPI-naive). *p < 0.05; paired Student’s t test.
(B) Heatmaps of transcriptome analysis from tumor biopsies of melanoma patients responding (responders) or not (non-responders) to anti-PD-1 therapy.
*p < 0.05; unpaired Student’s t test.
(C) Paired analysis comparing pre-treatment versus on-treatment melanoma biopsies of patients responding to anti-PD-1 therapy. The indicated inflammasome-
related genes were significantly upregulated during therapy. p < 0.05; paired Student’s t test.
(legend continued on next page)
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inflammasome-related genes that were significantly upregu-
lated in patients responding to anti-PD-1, suggesting that
they could function as a counter-regulatory mechanism in
response to treatment. Similar findings were observed in the
IPI-naive population (Table S5). We then performed a paired
analysis of tumor biopsies comparing pre-treatment and on
anti-PD-1 treatment from responding patients. We found 11
inflammasome-related genes that were significantly upregu-
lated during anti-PD-1 therapy compared with pre-treatment
biopsies (Figure 4C). Similar results were found when analyzing
the IPI-naive population (Table S6).
We then estimated the diversity of leukocyte populations infil-
trating tumors using the CIBERSORT method (Newman et al.,
2015). We observed increased relative frequencies of CD8+
T cells and activated memory CD4+ T cells during anti-PD-1
treatment versus pre-treatment in responders but not in progres-
sors (Figure 4D). Absolute number of leukocytes, CD8+ T cells,
and activated memory CD4+ T cells were also increased (Fig-
ure 4E). In patients responding to anti-PD-1 therapy, the total
number of leukocytes, as well as the frequency of CD8+ T cells
and activated memory CD4+ T cells, were positively associated
with expression of NLRP3 during ongoing treatment (Figure 4F).
These observations reinforce the concept that inflammasome
activation controls T cell immunity in patients treated with
immune checkpoint blockers.
To validate further these observations, we analyzed the
inflammasome gene expression profile in longitudinal tumor
biopsies from melanoma patients treated sequentially with
anti-CTLA-4 and anti-PD-1 mAb (Chen et al., 2016). These
authors studied gene expression profiling (GEP) via a custom
795-gene panel composed of immune and cancer-related
genes which did not include TMEM176A and TMEM176B.
The authors found no significant differences in GEP when
comparing responders versus progressors before anti-CTLA-4
or anti-PD-1 therapy. Consistently, we found no significant
expression of inflammasome-related genes at these stages
(Figures S6A, S6B, S7A, and S7B). These results are in agree-
ment with our findings from the analysis of the Riaz et al. cohort
at the pre-treatment stage (Tables S1–S4). However, the au-
thors found 411 genes that were significantly regulated (mostly
upregulated) in responders versus progressors following PD-1
blockade. In those patients, 15/16 inflammasome-related genes
were significantly upregulated in responders compared with
progressors (Figure 5A). We then performed a paired analysis
of the 16 inflammasome-related genes in biopsies of 5 re-
sponders and 7 progressors comparing gene expression
profiles before and during anti-PD-1 therapy. All these patients
had progressed to anti-CTLA-4 therapy. Critically, 5/5 patients
responding to anti-PD-1 mAb showed a significant upregulation
of inflammasome-related genes during anti-PD-1 treatment
(Figure 5B). Moreover, 4/7 patients who did not respond to
anti-PD-1 therapy significantly downregulated the inflamma-
some signature during PD-1 blockade (Figure 5B).(D and E) Paired study of the relative frequency (D) and absolute number (E) of the
biopsies from total patients responding to anti-PD-1 therapy analyzed by the CIB
(F) Association of NLRP3 expression with the frequency of total leukocytes, CD8+
therapy. Results show transcriptomics data obtained from tumor biopsies at the
See also Tables S1–S6.Thus, gene expression profiles from biopsies of two indepen-
dent cohorts of melanoma patients treated with immune
checkpoint blockers revealed strong association between in-
flammasome activation and clinical responses. These findings
support the notion that inflammasome activation contributes
to antitumor responses triggered by immune checkpoint
blockers and highlights the value of an ‘‘inflammasome activa-
tion’’ signature as a potential biomarker of response to immune
checkpoint blockade.
Pharmacologic Inhibition of TMEM176B Triggers
Inflammasome-Dependent Tumor Control and Improves
the Efficacy of Immune Checkpoint Blockers
To identify compounds capable of improving the efficacy of im-
mune checkpoint blockers by inhibiting TMEM176B-dependent
ion flux and triggering inflammasome activation, we set up an
in vitro assay. In brief, CHO-7 cells were transfected with
TMEM176B- and TMEM176A-mCherry. Cells were then loaded
with the Na+-sensitive fluorescent dye Asante NaTRIUMGreen 2
(ANG-2). We observed increased ANG-2 mean fluorescence in-
tensity in mCherry+ compared with mCherry cells (Figure 6A).
We then screened a library of compounds known to modulate
ion channel activity (Data S1). We found that both enantiomers
of BayK8644 potently inhibited TMEM176B-A-dependent Na+
influx, while they minimally affected TMEM176B-A-negative
cells (Figures 6A, 6B, and S8A), thus prompting the study of
these compounds. Whereas (+) BayK8644 is known to inhibit
L-type voltage-dependent Ca2+ channels, the () stereoisomer
activates those channels (Hamilton et al., 1987). Since both
isomers inhibit TMEM176B/A activity, it is unlikely that our
observations could be explained by their effects on Na+ influx
through the modulation of Ca2+ channels. In electrophysiology
studies using TMEM176B-overexpressing Xenopus oocytes, (+)
BayK8644 completely inhibited TMEM176B-dependent current
(Figure 6B). Therefore, we focused on the (+) isomer for func-
tional experiments.
We found that BayK8644 induced IL-1b secretion and cas-
pase-1 activation in LPS-primed WT but not in Tmem176b/
BMDCs (Figures 6C and S8B–S8D). Interestingly, BayK8644-
induced IL-1b secretion was inhibited by the Ca2+-activated
K+ channel (KCa) inhibitors tetraethylammonium and hydroxy-
chloroquine (Figure 6D). Thus, BayK8644 treatment on WT
BMDCs phenocopied Tmem176b deficiency. In THP-1-differ-
entiated macrophages, TMEM176B-dependent inhibition of
IL-1b secretion was prevented when these cells were treated
with BayK8644 (Figure 6E). These results suggest that
BayK8644 triggers inflammasome activation through inhibition
of TMEM176B.
We then explored whether BayK8644 treatment may control
tumor growth in vivo. Administration of BayK8644 significantly
increased survival of tumor-bearing WT but not Tmem176b/
mice (Figure 6F) compared with injection of vehicle control. Of
note, in vitro treatment of EG7 thymic lymphoma cells withindicated cell populations between pre-treatment versus on-treatment tumor
ERSORT method. *p < 0.05, **p < 0.01; paired Student’s t test.
T cells and activated memory CD4+ T cells in patients responding to anti-PD-1
on-treatment stage.
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BayK8644 did not induce apoptosis at similar doses as those de-
tected in plasma after intraperitoneal injection (Figure S8E). To
explore whether BayK8644 recapitulated the effects in tumor
growth control observed in untreated Tmem176b/ mice, we
evaluated its influence on inflammasome activation by disrupting
important components of this pathway.We found that BayK8644
significantly improved survival of WT but not Casp1/11/ tu-
mor-bearing mice (Figure 6G). Consistent with this observation,
BayK8644 increased the frequency of CD11b+ cDCs expressing
active caspase-1 in TDLN (Figure 6H). Moreover, BayK8644-
induced tumor control was mediated by CD8+ T cells as it
increased CD8+ T cell-dependent tumor cytotoxicity in vivo (Fig-
ure 6I), and depletion of CD8+ T cells completely abolished the
antitumor effect of this inhibitor (Figures 6J and S8F). Thus,
BayK8644 restrains EG7 tumor growth in a TMEM176B-, cas-
pase-1/11-, and CD8+ T cell-dependent manner, phenocopying
Tmem176b/mice. Moreover, BayK8644 significantly impaired
growth of CT26 colon cancer cells in BALB/c mice (Figures S8G
and S8H). Thus, BayK8644 emerges as an immunotherapeutic
agent that limits tumor growth by licensing inflammasome
activation.
Finally, we evaluated whether BayK8644 administration may
enhance the antitumor activity of immune checkpoint blockers.
Compared with mice receiving monotherapy, administration of
BayK8644 in combination with anti-CTLA-4 mAb significantly
improved survival of EG7 tumor-bearing mice (Figure 6K). More-
over, therapeutic administration of BayK8644 in mice with es-
tablished tumors significantly improved the antitumoral effect
of anti-PD-1 treatment (Figure 6L), whereas BayK8644 mono-
therapy was not effective in this therapeutic protocol (data not
shown). Interestingly, combination of anti-PD-1 with BayK8644
was associated with an increased absolute number and per-
centage of TCRb+ CD4+ RORgt+ T cells in TDLN (Figure S8I)
and increased frequency of tumor-specific CD8+ T cells within
the tumor microenvironment (Figure 6M) compared with anti-
PD-1 monotherapy. Depletion of CD8+ T cells in mice treated
with anti-PD-1 plus BayK8644 abrogated antitumor immunity
(Figure 6N). This observationmight be explained by concomitant
CTL-mediated mechanisms required for both the antitumor
activity of BayK8644 (Figures 6J and S8F) and anti-PD-1 mAb
(Sharma and Allison, 2015). Thus, as expected, combination
treatment strongly relies on the CD8+ T cell compartment.
Furthermore, BayK8644 significantly enhanced the antitumoral
effect of anti-PD-1 therapy in mice bearing 5555melanoma (Fig-
ure 6O), whereas this effect was apparent in LL/2 lung cancer
(Figures S8J and S8K) and MC38 colon cancer (Figures S8L
and S8M) models, albeit not reaching statistical significance.
Moreover, whereas BayK8644 reinforced the antitumor effects
of anti-PD-1 treatment in mouse melanoma, it did not enhance
tumor growth inhibition induced by anti-CTLA-4 and anti-PD-1Figure 5. Analysis of the Inflammasome Signature in Tumor Biop
Blockers
(A) Log2-transformed normalized NanoString counts for the indicated inflammaso
anti-PD-1mAb. The results for responding and non-responding patients as define
****p < 0.0001; unpaired Student’s t test.
(B) Paired analysis of the 16 inflammasome-related genes studied in (A) compa
responding (n = 5) or not responding (n = 7) to anti-PD-1 therapy. *p < 0.05, ***p
See also Figures S6 and S7.combination therapy, at least in this model (Figure S8O). Given
the pharmacologic impact of channel inhibitors in cardiomyo-
cyte function, we finally examined whether BayK8644 may
lead to acute cardiac toxicity. Notably, BayK8644 treatment
was not associated with electrocardiographic nor echocardio-
graphic alterations 30 min after intravenous injection compared
with mice treated with vehicle control (Tables 1 and 2). Thus,
pharmacological inhibition of TMEM176B represents a potential
therapeutic approach to unleash inflammasome activation,
leading to potentiation of CD8+ T cell-dependent antitumor
immunity.
DISCUSSION
In this study, we demonstrate a central role of the inflamma-
some in reinforcing CD8+ T cell-dependent antitumor immunity
and enhancing the efficacy of checkpoint blockade therapies.
In particular, we demonstrate a key role of TMEM176B as nega-
tive regulator of inflammasome activation. Whereas most
immunotherapeutic modalities have focused on drugs targeting
adaptive components of the immune system, innate immune
pathways may represent additional anticancer targets (Woo
et al., 2014).
Although recently proposed to play a role in immunotherapy
(Mangan et al., 2018), the direct contribution of IL-1b/IL-18 in-
flammasomes to antitumor immunity and adaptive checkpoint
blockade remains elusive (Karki et al., 2017). Here we identify
a therapeutic strategy that reinforces antitumor responses by
targeting TMEM176B and promoting inflammasome disinhibi-
tion. Our results suggest that inflammasome activation plays a
central role in antitumor immunity triggered by anti-CTLA-4
and anti-PD-1 mAb. Although experiments in Nlrp3/ animals
did not reach statistical significance, studies in animals lacking
the downstream effectors Casp1/11 did. These observations
suggest that different inflammasomes could mediate the antitu-
moral effect triggered by anti-CTLA-4 and anti-PD-1 therapies.
Accordingly, analysis of anti-PD-1-treated melanoma patients
suggested that NLRP6, NLRP7, AIM2, and NLRC4 inflamma-
somes might contribute to antitumor responses unleashed by
checkpoint blockers. Although the requirement of caspase-1
autoproteolysis can differ among different inflammasomes
(Broz et al., 2010), and caspase-1 may cleave other proteins
than IL-1b and IL-18 (Sokolovska et al., 2013), to our knowl-
edge, caspase-1/11 activation mostly depends on inflamma-
somes. Thus, it is unlikely that observations in Casp1/11/
and Tmem176b/Casp1/ mice could involve inflamma-
some-independent mechanisms.
Our results suggest that TMEM176B might be a predictive
marker of response to anti-PD-1 therapy. In addition, TMEM176B
expression in the tumor stromawas associatedwith poor survivalsies from Melanoma Patients Treated with Immune Checkpoint
me-related genes in melanoma tumor biopsies from patients being treated with
d by Chen et al. (2016). Mean ± SD are shown. *p < 0.05, **p < 0.01, ***p < 0.001,
ring pre-treatment and on-treatment tumor biopsies from melanoma patients
< 0.001, ****p < 0.0001; paired Student’s t test.
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Table 1. Effect of BayK8644 on Electrocardiographic Parameters
RR P wave PR QRS QT QTc
Controla 150 ± 18b 16.0 ± 0.0 32.0 ± 2.0 13.3 ± 1.2 53.3 ± 4.1 43.6 ± 0.8
Vehicle 143 ± 9 14.7 ± 0.7 32.0 ± 1.5 13.7 ± 1.8 56.0 ± 2.5 46.8 ± 0.8
Control 130 ± 2 15.2 ± 1.2 32.8 ± 1.9 11.0 ± 0.4 51.2 ± 2.7 45.1 ± 2.7
BayK8644 120 ± 5 15.4 ± 1.2 32.6 ± 1.8 11.2 ± 0.6 54.4 ± 1.9 49.7 ± 0.8
aValues before injection of vehicle control or BayK8644.
bMean ± SD are expressed in ms.in colorectal cancer patients, suggesting a potential role of this
ion channel as a prognostic factor. Interestingly, TMEM176B
was associated with diminished NLRP3 and IL1B expression in
macrophages infiltrating human melanoma, suggesting that this
ion channel may function as an innate checkpoint signal that
hinders immune responses in the tumor microenvironment. How-
ever, our results in experimental models support a key role for
TMEM176B in themodulation of inflammasome activationmostly
in TDLNduring the induction phaseof antitumor responses. Thus,
TMEM176B-dependent immune inhibitory mechanisms may
operate within the tumor microenvironment and TDLN.Figure 6. Targeting TMEM176B with BayK8644 Triggers Inflammasom
(A) TMEM176B activity in CHO-7 cells treated or not with BayK8644. Representa
conditions (left) and quantification of ANG-2 mean fluorescence intensity (MFI) (r
two-way ANOVA test.
(B) TMEM176B-dependent conductance assessed in Xenopus oocytes following
acetate (PMA) stimulation. Representative currents (left) and determination of T
***p < 0.001; one-way ANOVA test.
(C) Determination of IL-1b in culture supernatants fromWT and Tmem176b/BM
experiment representative of three is shown. *p < 0.05; two-way ANOVA test.
(D) Determination of IL-1b in culture supernatants from WT BMDCs primed wit
tetraethylammonium (TEA) (2 mM) or HCQ (10 mM). One experiment representat
(E) Determination of IL-1b in culture supernatants from THP-1-differentiated mac
treated or not with LPS plus nigericine (LPS/Nig) in the presence of ethanol (ve
inhibition, IL-1b levels (pg/mL) were incorporated to the formula: [GFP/LPS/Nig – G
three is shown. *p < 0.05; Student’s t test.
(F andG) Survival ofWT (F andG) and Tmem176b/ (F) orCasp1/11/ (G) mice i
2–15 after tumor cell injection. *p < 0.05, **p < 0.01; log rank (Mantel-Cox) test.
(H) Caspase-1 activation in TDLN from WT mice inoculated with EG7 tumor cel
resected 14 days after tumor injection and caspase-1 activation was studied by
(I) In vivo cytotoxicity against OVA-expressing cells in WT mice inoculated with
cytotoxicity was determined. *p < 0.05; Student’s t test.
(J) Survival of tumor (EG7)-bearing WT mice treated with BayK8644 or vehicle c
Vehicle versusWT +BayK8644: *p < 0.05;WT +BayK8644 versusWT +BayK8644
rank (Mantel-Cox) test.
(K) Survival of tumor (EG7)-bearing WTmice treated or not with BayK8644, anti-C
versus BayK8644 + anti-CTLA-4: **p < 0.01; BayK8644 versus BayK8644 + anti-C
anti-CTLA-4: ns; untreated versus BayK8644: ns; log rank (Mantel-Cox) test.
(L) Survival of tumor (EG7)-bearing WTmice treated or not with 250 mg anti-PD-1
day since day 9 (when all mice had established tumors) until day 21. *p < 0.05; l
(M) Frequency of OVA-specific CD8+ T cells as determined by flow cytometry usin
with anti-PD-1 alone or anti-PD-1 + BayK8644 in a therapeutic protocol as in (L)
(N) Survival of tumor (EG7)-bearing WTmice treated or not with BayK8644 plus an
log rank (Mantel-Cox) test.
(O) Survival ofWTmice inoculated with 5,555melanoma cells and left untreated or
both. All animals had established tumors when BayK8644 treatment was star
BayK8644 versus BayK8644 + anti-PD-1: ns; anti-PD-1 versus BayK8644 + anti-
rank (Mantel-Cox) test.
In (F), (G), and (J–O) the ratio represents the number of surviving mice/total injec
Mean ± SD are shown.
See also Figure S8.Sustained K+ efflux through the voltage-gated (Kv1.3) or Ca
2+-
activated (KCa3.1) K+ channels has been shown to reinvigorate
tumor-infiltrating T cells (Eil et al., 2016). The results presented
here suggest that Ca2+-induced K+ efflux in DCs may promote
antitumor immunity by triggering inflammasome activation, a
process that is repressed by TMEM176B.
In conclusion, our study links inflammasome activation to anti-
tumor responses triggered by immune checkpoint blockers,
highlighting a central role for TMEM176B, an ion channel ex-
pressed on myeloid cells, in repression of T cell-dependent im-
munity. Further efforts should be aimed at evaluating the clinicale-Dependent Antitumor Immunity
tive flow cytometry histograms displaying ANG-2 fluorescence at the indicated
ight). One experiment representative of five is shown. **p < 0.01, ***p < 0.001;
addition of 10 mM (+) BayK8644 to extracellular buffer during phorbol myristate
MEM176B current at 800 s post-extracellular acidification (right) are shown.
DCs primed for 3 hwith LPS and then treated or not with 2.5 mMBayK8644. One
h LPS and then treated with 10 mM BayK8644 alone or in combination with
ive of three is shown. *p < 0.05, **p < 0.01; one-way ANOVA test.
rophages transfected with GFP or TMEM176B/GFP-coding plasmids and then
hicle) or 5 mM BayK8644. To calculate the extent of TMEM176B-dependent
FP untreated] – TMEM176B/LPS/Nig3 100. One experiment representative of
noculatedwith EG7 tumor cells and treatedwith 1mg/kg BayK8644 i.p. on days
ls and then treated or not with 1 mg/kg BayK8644 on days 2–13. TDLN were
flow cytometry using the FLICA1 reagent. *p < 0.05; Student’s t test.
EG7 tumor cells treated or not with BayK8644 as in (F). At day 15, in vivo
ontrol, receiving or not anti-CD8 depleting antibody. ns, not significant. WT +
+ anti-CD8: *p < 0.05;WT + Vehicle versusWT +BayK8644 + anti-CD8: ns; log
TLA-4 mAb, or BayK8644 plus anti-CTLA-4 mAb. ns, not significant. Untreated
TLA-4: ns; anti-CTLA-4 versus BayK8644 + anti-CTLA-4: ns; untreated versus
mAb at days 6, 9, and 12 after tumor inoculation. BayK8644 was injected every
og rank (Mantel-Cox) test.
g fluorescent MHC pentamers in EG7 tumor suspensions fromWTmice treated
. *p < 0.05; unpaired Student’s t test.
ti-PD-1 mAb in the absence or presence of anti-CD8 depleting mAb. *p < 0.05;
treated either with anti-PD-1mAb (days 6, 9, and 12), BayK8644 (days 9–21), or
ted. ns, not significant. Untreated versus BayK8644 + anti-PD-1: *p < 0.05;
PD-1: ns; untreated versus anti-PD-1: ns; untreated versus BayK8644: ns; log
ted mice. For these experiments we used C57BL/6 mice.
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Table 2. Effect of BayK8644 on Echocardiographic Parameters
Vehicle BayK8644
Cardiac frequency (bpm) 457 ± 50 515 ± 35
Left ventricular telediastolic wall
thicknesses (mm)
1.0 ± 0.0 1.1 ± 0.1
Left ventricular telediastolic
diameter (mm)
3.2 ± 0.2 2.8 ± 0.2
Left ventricular ejection fraction (%) 82 ± 1 93 ± 2
E/A ratio 1.7 ± 0.1 1.5 ± 0.1
Isovolumic relaxation time (ms) 15.0 ± 0.0 18.8 ± 0.2
E-wave deceleration time (ms) 37.7 ± 1.8 33.4 ± 2.5
Mean ± SD are expressed.efficacy and safety of inflammasome disinhibition in the treat-
ment of cancer patients, particularly those resistant to current
immunotherapies.
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Colon cancer tissue array 90 tumor cases with
survival information.
US Biomax, Inc Cat# HCol-Ade180Sur-04
Chemicals, Peptides, and Recombinant Proteins
TRIzol Reagent. Invitrogen Cat#15596026
M-MLV Reverse Transcriptase. Invitrogen Cat# 28025013
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Fast SYBR Green Master Mix. Applied Biosystems. Cat#4385612
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ATP Sigma Cat# 10127531001 CAS: 51963-61-2
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Iberiotoxin Sigma Cat# I5904
Hydroxychloroquine Sigma Cat# H0915 CAS: 747-36-4
TEA Sigma Cat# T2265 CAS: 56-34-8
(-) BayK8644 Sigma Cat# B-133 CAS: 98625-26-4
Capsaicin Sigma Cat# M2028 CAS: 404-86-4
1-(1-Adamantyl)ethylamine hydrochloride Sigma Cat# 390593 CAS: 1501-84-4
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Lipofectamine 2000 Thermo Fisher Cat# 11668027
Fura-2 Thermo Fisher Cat# F1201 CAS: 108964-32-5
DDAO-SE Thermo Fisher Cat# C34564
Asante NaTRIUM Green-2 AM Abcam Cat# Ab142802
FLICA 660 Caspase-1 Assay (FLICA1) Immunochemistry Cat# 9122
SCREEN-WELL Ion Channel ligand library Enzo Life Sciences Cat# BML-2805
Critical Commercial Assays
Mouse IL-1b ELISA Biolegend Cat# 432603
Human IL-1b ELISA BD Bioscience Cat# 557953
Mouse IL-18 ELISA kit MBL Cat# 7625
Amaxa Cell Line Nucleofector Kit V Lonza Cat# VCA-1003
EnVision+ System- HRP Labelled Polymer Dako Cat# K4002
Deposited Data
Bulk RNA expression data Riaz cohort (Riaz et al., 2017) https://github.com/riazn/bms038_analysis/
tree/master/data
Normalized single cell expression data. (Jerby-Arnon et al., 2018) GEO: GSE115978
Mendeley dataset https://data.mendeley.com/datasets/publish-
confirmation/gvj6fc2b8v/1
Normalized NanoString nCounter data (Chen et al., 2016)
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THP-1 ATCC Cat# TIB-202 RRID:CVCL_0006
CHO-K1 ATCC Cat# CCL-61 RRID:CVCL_0214
LL/2 (LLC1) ATCC Cat# CRL-1642 RRID:CVCL_4358
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Melanoma 5555 Richard Marais’ lab N/A
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Mouse: C57BL/6J Institut Pasteur Montevideo N/A
Mouse: Balb/C Institut Pasteur Montevideo N/A
Mouse: Tmem176b-1-/- Cristina Cuturi’s lab N/A
Mouse: Tmem176b +/+- Cristina Cuturi’s lab N/A
Mouse: Tmem176b -/-Casp1-/- This paper N/A
Mouse: Nlrp3-/- (B6.129S6-Nlrp3tm1Bhk/J The Jackson Laboratory Cat# 021302 RRID:IMSR_JAX:021302
Mouse: Casp1/11-/- (B6N.129S2-Casp1tm1Flv/J) The Jackson Laboratory Cat# 016621 RRID:IMSR_JAX:016621
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C57BL/6J The Jackson Laboratory Cat# 000664 RRID:IMSR_JAX:000664
C57BL/6NJ The Jackson Laboratory Cat# 005304 RRID:IMSR_JAX:005304
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Primers for RORgt (mRNA) see Table S7 This paper N/A
Primers for Il17a, see Table S7 This paper N/A
Primers for Foxp3, see Table S7 This paper N/A
Primers for Tgfb1, see Table S7 This paper N/A
Primers for Il10, see Table S7 This paper N/A
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Primers for Tnfa, see Table S7 This paper N/A
Primers for Ctla4, see Table S7 This paper N/A
Primers for Ccl22, see Table S7 This paper N/A
Primers for Ccl5, see Table S7 This paper N/A
Primers for Il12, see Table S7 This paper N/A
Primers for Il4, see Table S7 This paper N/A
Primers for Gata3, see Table S7 This paper N/A
Primers for Tbx21, see Table S7 This paper N/A
Primers for Cebpb, see Table S7 This paper N/A
Primers for Ccl19, see Table S7 This paper N/A
Primers for Il6, see Table S7 This paper N/A
Primers for Fas, see Table S7 This paper N/A
Primers for Pdl1, see Table S7 This paper N/A
Primers for Tmem176b, see Table S7 This paper N/A
Primers for Gapdh, see Table S7 This paper N/A
Recombinant DNA
pcDNA3.1-rTmem176b-GFP Cédric Louvet N/A
pcDNA3.1GFP José Badano N/A
pSecTag2B-PS-Tmem176b-V5His Cédric Louvet N/A
pSecTag2b-PS-rTmem176b-2mcherry Cédric Louvet N/A
Software and Algorithms
FlowJo vX.0.7 Flowjo, LLC N/A
GraphPad Prism 6 GraphPad Software, Inc. N/A
Rmagic 1.3.0 (Van Dijk D et al., 2018) https://github.com/KrishnaswamyLab/MAGIC
CIBERSORT (Newman et al., 2015) https://cibersort.stanford.eduCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marcelo
Hill (mhill@pasteur.edu.uy).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Animals
Six-to-ten weeks old male or female C57BL/6 or BALB/c mice were used (Jackson Lab; Bar Harbor, ME) and bred for up to 20 gen-
erations at the Institut Pasteur Montevideo or at the Institute of Biology and Experimental Medicine (IBYME), Buenos Aires. All
experiments were performed according to local regulation and approved by the Institut Pasteur de Montevideo and by the Institu-
tional Committee for Care and Use of Laboratory Animals (CICUAL) at IBYME.
Tmem176b-/- mice were generated in the 129/SvJ strain and heterozygous mice were backcrossed for 10 generations onto the
C57BL/6 background (Janvier, Saint Berthevin, France) as reported (Segovia et al., 2014). Nlrp3-/- (B6.129S6-Nlrp3tm1Bhk/J;
021302) and Casp1/11-/- (B6N.129S2-Casp1tm1Flv/J; 016621) were from Jackson Laboratory. Nlrp3-/- animals were compared to
000664 C57BL/6J, and Casp1/11-/- mice to 005304 C57BL/6NJ. Tmem176b-/-Casp1-/- mice were generated by microinjectinge3 Cancer Cell 35, 767–781.e1–e6, May 13, 2019
Crispr/Cas9 targetingCasp1 in Tmem176b-/- embryos. F1 animals were genotyped and heterozygousmicewere crossed to generate
F2 homozygous Tmem176b-/-Casp1-/- animals. Casp1 deficiency was confirmed by Western blot (Figure S1). All animal strains
including Tmem176b-/-, Tmem176b+/+ WT (issued from littermate controls), C57BL/6J, Nlrp3-/-, C57BL/JN, Casp1/11-/- and
Tmem176b-/-Casp1-/- were bred at a specific pathogen-free animal facility (Institut Pasteur, Montevideo).
Cell Lines
EG7 (expressing OVA antigen), LL2, CT26, THP-1 and CHO-K1 cell lines were purchased from ATCC (Manassas, VA). MC38 cells
were from Kerafast (Boston, MA). The 5555 melanoma cell lines were kindly provided by R. Marais (Cancer Research UK, Manches-
ter) and cultured as described (Hirata et al., 2015).
Tumor Models and Treatments
C57BL/6mice were injected s.c with 1 x 106MC38 colon cancer cells, 1 x 105 LL2 lung cancer cells, 2.5 x 105 5555melanoma cells or
1 x 106 EG7 thymic lymphoma cells. BALB/C animals were injected with 1 x 105 CT26 colon cancer cells. Injection was performed
alternating one WT and one Tmem176b-/- mouse until completing both groups. In treated animals, alternation was done between
drug- and vehicle-treated animals. Tumor growth was measured manually every 2-3 days with a caliper. The two major diameters
were taken. Mice were sacrificed when one of the diameters reached 2 cm. In experiments where anti-IL-1b, anti-IL-17A or control
IgGwere used, 4 mg antibodywas injected i.p 7 days after inoculation of tumor cells. Injections were repeated every five days until day
27 post-injection or euthanasia. For depletion of CD8+ T cells, 100 mg YTS 169.4 antibody was injected every three days starting from
the day before tumor inoculation. Depletion was confirmed in the spleen by flow cytometry. For administration of anti-CTLA-4mAb or
control IgG, 100 mg antibody was given i.p starting from day 6 after tumor inoculation. Injections were repeated every three days until
day 12. Anti-PD-1 mAb or control IgG was injected (250 mg i.p) starting from day 6 and every three days until day 12. BayK8644 or
vehicle control (ethanol) was given i.p at 1 mg/kg since day 3 until day 15 after tumor inoculation. In animals treated with BayK8644
and anti-CTLA-4 mAb, BayK8644 was injected at days 3-15 every day and anti-CTLA-4 at days 6, 9 and 12 after tumor inoculation. In
mice treated with BayK8644 and anti-PD-1 mAb, treatment with the former started at day 9 and repeated every day until day 21 after
tumor inoculation. Anti-PD-1 treatment started at day six after tumor inoculation and repeated every three days until day 12.
In Vivo Inflammasome Activation
C57BL/6 animals were injected i.p with 20mg/kg ATP. Four hr later, peritoneal lavage was performed using 5ml PBS. Peritoneal cells
were centrifuged and stained with anti-CD11b, anti-Ly6C and anti-Ly6G antibodies. Cells were analyzed by flow cytometry. The
percentage of Ly6Cint Ly6Ghi cells within the CD11b+ cell compartment (neutrophils) was determined. The absolute number of
neutrophils was calculated for each condition.
In Vitro Inflammasome Activation
Bone marrow-derived DCs (BMDCs) were differentiated by culturing bone marrow cells for 8 days in the presence of 0.4 ng/ml
GM-CSF. At day 8, adherent cells were >95% CD11c+CD11b+MHC IIint. Cells were stimulated for 3 hr with 0.25 mg/ml LPS, washed
and treated with the indicated doses of ATP or nigericin. The presence of IL-1b was assessed in culture supernatants by ELISA
(Biolegend, 432603). To determine Caspase-1 activation, BMDCs were stained with FLICA1 45 min after ATP or nigericin stimulation
and analyzed by flow cytometry. For Western blot, culture supernatants from BMDCs stimulated in the absence of FBS were
precipitatedwith 20% (v/v) TCA andwashedwith acetone. Cell lysateswere generatedwith RIPA buffer in the presence of a protease
inhibitor cocktail. Cell lysates and precipitates from culture supernatants were electrophoresed, blotted and probed with anti-
Caspase-1 (Adipogen, AG-20B-0042) or anti-IL-1b (Santa Cruz Biotechnol, sc-7884) antibodies.
THP-1 Transfection and Inflammasome Activation
THP-1 monocytes were differentiated into macrophages by treatment with 0.1 mMPMA for 48 hr. Macrophages (2.5 x 106) were then
detached using trypsine and nucleofected with the GFP or GFP-TMEM176B coding pcDNA1.3 plasmids using the Amaxa Cell Line
Nucleofector Kit V-Lonza and nucleofector device (Amaxa). Sixteen hr later, cells were treated for 3 hr with 0.25 mg/ml LPS. Cells were
washed and treated for 2 hr with 2.5 mM nigericin.
METHOD DETAILS
Cytosolic Ca++ Determination
BMDCs cultured on glass coverslips were loaded with 1 mM Fura-2 (ratiometric Ca++-sensitive probe) for 45 min in the dark. Cells
were then washed and analyzed by time-lapse microscopy at 37C. Fluorescence emission intensity at 510 nm was determined
in individual wells alternating excitation wavelengths of 340 and 380 nm every 3 s. ATP was added when indicated at 0.5 mM.
In Vivo Cytotoxicity Assay
Splenocytes from naive C57BL/6 mice were stained alternatively with 0.8 (high) or 0.08 mM (low) DDAO-SE probe. The high DDAO
population was loaded for 60 min at 37C with 50 mM SIINFEKL OVA peptide. After three washes, the high and low population were
mixed at 1:1 ratio. The mixed cells (2 x 106) were injected i.v in WT, Tmem176b-/- or Tmem176b-/-Casp1-/- naive or tumor-bearingCancer Cell 35, 767–781.e1–e6, May 13, 2019 e4
mice. Four hr later, mice were sacrificed and the spleens harvested. Splenocytes were analyzed by flow cytometry to assess DDAO
high and low populations. Specific cytotoxicity was calculated using the following formula:
% specific lysis = (1-[rnaive/rtumor bearing]) 3 100r = %DDAOlow cells / %DDAOhigh cells
Screening of TMEM176B Inhibitors
CHO cells were transfected with pSecTag2B-PS-TMEM176A-mCherry and pSecTag2B-PS-TMEM176B-V5His plasmids using
Lipofectamine 2000 for 4 hr, washed and cultured for 24 hr. Cells were then loaded with 1 mM ANG-2 for 30 min at 37C, washed
and incubated in 140 mM Na+-containing phosphate buffer or 140 mM NMDG to substitute Na+ in the presence of different doses
of tested drugs or vehicle controls. Cells were then analyzed by flow cytometry using a BD Accuri C6 cytometer equipped with a
488 nm laser. ANG-2 emission was detected using a band-pass filter 530/30 and mCherry was determined using a 670 LP filter.
FlowJo vX.0.7 softwarewas used for data analysis. MFI fromNMDG-containing solutions was subtracted toMFI fromNa+-containing
solutions. Amaximum of two drugs was studied in each experiment. Screened drugs were from SCREEN-WELL Ion Channel ligand
library (Enzo Life Sciences; Farmingdale, NY).
Immunohistochemistry of Human Colon Microarrays
Expression of TMEM176B was analyzed by immunohistochemistry on 90 specimens of human colon tumors (US Biomax, Inc; Rock-
ville, MD). Briefly, antigenic recovery was done by boiling slides in a pressure cooker for 10 min in the presence of alkaline buffer
(10 mM Tris, 1 mM EDTA, 0.05% Tween 20, pH 9.0). Anti-TMEM176B antibody (2.5 mg/ml; Abcam, ab103929) or control rabbit
IgG was incubated ON at 4C. Staining was verified using EnVision+ System- HRP-labelled polymer anti-rabbit (Dako/Agilent, Santa
Clara CA). Slides were counterstained with Meyer’s hematoxylin, analyzed by two independent researchers in a blind fashion and
categorized as high or low/negative TMEM176B expression in the stroma and parenchyma. Expression levels were then correlated
with survival information provided by US Biomax.
Electrophysiology Experiments
Oocytes were surgically removed fromMS222 (0.4%)-anesthetized Xenopus laevis female and dissociated under gentle agitation by
a 2–3 hr incubation in an OR2 solution (82 mM NaCl; 2 mM KCl; 1 mMMgCl2; 5 mM HEPES pH 7.2) supplemented with collagenase
1A (1 mg/ml). Oocytes were then injected with 40 nl of in vitro synthesized Tmem176bmRNA at 1 mg/ml (mMessage mMachine Ultra
kit). Tmem176b was fused to a signal peptide sequence (N-terminal) from pSecTag2B (Invitrogen, Carlsbad, CA) and to V5 + 6-His
tags (C-terminal). The day after injection, oocytes were placed in a pH 8.0 solution (100 mM NaCl, 3 mM KCl, 2 mM MgCl2, 15 mM
HEPES pH 8.0) changed daily. Two to three days later, currents were recorded in two-electrode voltage-clamp using a genclamp500
amplifier (Axon Inst., Foster City, CA) interfaced to a personal computer using the Digidata 1200 interface and the pClamp software
(v 7.0; Axon Inst.). Prior to recording, oocytes were incubated in PMA at 0.1 mM in pH 8.0 solution for 20–30 min. Currents were filtered
at 100 Hz and digitalized at 0.5 kHz before storage and further analysis. During recording, oocytes were continuously superfused
with the pH 8.0 solution. The currents were quantified 5–15 min after holding the extracellular pH at 5.0. In TMEM176B-expressing
oocytes, induction of an inward current was obtained by switching to a pH 5.0 solution.
Quantitative RT-PCR
Total RNA from tumors and lymph nodes was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA). Reverse transcription was
performed usingM-MLVReverse Transcriptase and randomprimers followingmanufacturer’s instructions (Invitrogen). Gene expres-
sion was assessed with the Fast SYBR Green Master Mix reagent (Applied Biosystems, Foster City, CA). Mouse primers used in this
study (Table S7) were all designed over different exons to prevent amplification of genomic DNA. Real-time PCR was performed
using the ViiA 7 Real-Time PCRSystem (Applied Biosystems) or Eco Real-Time PCRSystem (Illumina). Gene expression was normal-
ized using glyceraldehyde 3-phosphate dehydrogenase and expressed in arbitrary units using the 2DDCt method.
Gene Expression Analysis
Normalized NanoString nCounter data were analyzed from Chen et al. (2016). Gene expression data from Riaz et al (2017) were
obtained from their GitHub repository (https://github.com/riazn/bms038_analysis/tree/master/data). RNA-seq count data were
normalized to FPKM (fragment per kilobase per million) through the Bioconductor R package DESeq2 1.18.1. The on-treatment
biopsy from patient 32 was excluded from further analyses since it presented extreme expression values.
CIBERSORT Analysis
The leukocyte signature matrix LM22 (547 genes) which discriminates 22 types of tumor-infiltrating immune cells was used for anal-
ysis. Normalized gene expression data from Riaz et al. (2017) cohort were processed with the CIBERSORT web tool (http://cibersort.
stanford.edu/) setting no quantile normalization and 1.000 permutations as parameters. All samples were run with both relative ande5 Cancer Cell 35, 767–781.e1–e6, May 13, 2019
absolute modes. The first mode infers the relative cellular fraction for each cell of the LM22matrix and the second calculates a score
that reflects the absolute proportion of each cell type in the mixture.
Single Cell RNA-Seq Data Analysis
Normalized single cell expression data from Jerby-Arnon et al. (2018) was obtained from Gene Expression Omnibus (Accession
number GSE115978). To study gene correlations, the expression matrix was processed with the software MAGIC (van Dijk et al.,
2018) to deal with the undersampling of mRNA known as dropouts. R implementation of the MAGIC algorithm with default param-
eters (Rmagic v1.3.0) was applied. For correlation analysis, Spearman’s Rank Correlation test was used.
Statistical Analyses
Statistical analyses were performed either by R project or GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). Survival
analyses were done with the Log-rank (Mantel-Cox) test. Comparison of two experimental conditions was done with paired or
unpaired Student’s t test. Comparison of multiple conditions was done with one or two-way ANOVA tests. Differences in gene
expression and CIBERSORT scores between responder and non-responder groups were assessed using the unpaired t-test
when normality assumption was met. Otherwise, Mann-Whitney U test was used. Differences between matched pre- and on-treat-
ment samples were evaluated with paired t-test when normality assumption was met or otherwise with Wilcoxon signed-rank test.
For correlation analysis, the Pearson coefficient was used when samples passed the normality test. Spearman coefficient was used
for all other cases. Shapiro-Wilk test was performed to evaluate the normality assumption for all samples.
DATA AND SOFTWARE AVAILABILITY
Mendeley dataset: https://data.mendeley.com/datasets/publish-confirmation/gvj6fc2b8v/1.Cancer Cell 35, 767–781.e1–e6, May 13, 2019 e6
